| Literature DB >> 22719223 |
Mingzhou Li1, Honglong Wu, Tao Wang, Yudong Xia, Long Jin, Anan Jiang, Li Zhu, Lei Chen, Ruiqiang Li, Xuewei Li.
Abstract
It is well established that the metabolic risk factors of obesity and its comorbidities are more attributed to adipose tissue distribution rather than total adipose mass. Since emerging evidence suggests that epigenetic regulation plays an important role in the aetiology of obesity, we conducted a genome-wide methylation analysis on eight different adipose depots of three pig breeds living within comparable environments but displaying distinct fat level using methylated DNA immunoprecipitation sequencing. We aimed to investigate the systematic association between anatomical location-specific DNA methylation status of different adipose depots and obesity-related phenotypes. We show here that compared to subcutaneous adipose tissues which primarily modulate metabolic indicators, visceral adipose tissues and intermuscular adipose tissue, which are the metabolic risk factors of obesity, are primarily associated with impaired inflammatory and immune responses. This study presents epigenetic evidence for functionally relevant methylation differences between different adipose depots.Entities:
Keywords: DNA methylation; MeDIP-seq; pig; subcutaneous adipose tissue; visceral adipose tissue
Mesh:
Year: 2012 PMID: 22719223 PMCID: PMC3372887 DOI: 10.7150/ijbs.4493
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1Heat map of co-methylated gene sets in eight adipose tissues. Three SATs (abdominal subcutaneous adipose (ASA), inner layer of backfat (ILB), upper layer of backfat (ULB)); four VATs (greater omentum (GOM), mesenteric adipose (MAD), retroperitoneal adipose (RAD), pericardial adipose (PAD)); and intermuscular adipose (IAD). Pair-wise correlations between genes residing in all the gene sets were plotted. Gene pairs strongly positively or negatively correlated are shown in red or green, respectively. Colour intensity represents the strength of the correlation. The co-methylated gene sets are indicated by squares and are ordered by the number of genes; thus with the largest gene set - containing the largest number of genes - in the upper left corner and the smallest gene set in the lower right corner.
Figure 2Correlations between co-methylated gene sets in eight adipose tissues and phenotypic traits of obesity. Log10 P-values for Spearman rank correlation coefficients between the methylation values of the gene sets and the different phenotypic traits of obesity are shown. The gray shadow represents the Bonferroni corrected P-values that are greater than 0.001. SFA, MUFA, and PUFA, denote saturated, monounsaturated, and polyunsaturated fatty acids, respectively.
Top ten Gene Ontology (GO) and KEGG pathway categories enriched for co-methylated gene sets that correlated with phenotypic traits of obesity.
| Correlated trait | Tissue (gene sets order No.) | Functional category | Term description | Involved gene No. | |
|---|---|---|---|---|---|
| Apo-A1 | ASA (2) | GO-BP | Cellular carbohydrate biosynthetic process | 0.002 | 12 |
| GO-BP | Regulation of small GTPase mediated signal transduction | 0.003 | 27 | ||
| GO-BP | Positive regulation of growth | 0.006 | 11 | ||
| GO-BP | Carbohydrate biosynthetic process | 0.008 | 14 | ||
| GO-MF | GTPase regulator activity | 0.009 | 35 | ||
| GO-MF | Small GTPase regulator activity | 0.009 | 27 | ||
| GO-BP | Glycerolipid metabolic process | 0.021 | 20 | ||
| GO-BP | Positive regulation of cell proliferation | 0.025 | 34 | ||
| GO-BP | Cholesterol metabolic process | 0.029 | 13 | ||
| GO-BP | Response to steroid hormone stimulus | 0.040 | 18 | ||
| HDL | ILB (5) | GO-MF | SH2 domain binding | 0.003 | 17 |
| GO-MF | Manganese ion binding | 0.008 | 25 | ||
| GO-BP | Gastrulation | 0.009 | 20 | ||
| GO-BP | Regulation of response to external stimulus | 0.009 | 26 | ||
| GO-MF | Enzyme activator activity | 0.013 | 34 | ||
| GO-BP | Regulation of growth | 0.015 | 34 | ||
| GO-BP | Regulation of smoothened signaling pathway | 0.016 | 16 | ||
| GO-BP | Positive regulation of anti-apoptosis | 0.018 | 17 | ||
| GO-BP | Striated muscle tissue development | 0.032 | 22 | ||
| GO-BP | Cell projection assembly | 0.032 | 20 | ||
| LDL | ASA (1) | GO-BP | Cellular carbohydrate biosynthetic process | 0.001 | 12 |
| GO-BP | Purine ribonucleoside triphosphate biosynthetic process | 0.002 | 15 | ||
| GO-BP | Cellular polysaccharide biosynthetic process | 0.002 | 8 | ||
| GO-BP | Positive regulation of biosynthetic process | 0.003 | 72 | ||
| GO-BP | ATP biosynthetic process | 0.003 | 14 | ||
| GO-BP | Ribonucleoside triphosphate biosynthetic process | 0.003 | 15 | ||
| GO-BP | Positive regulation of macromolecule biosynthetic process | 0.005 | 67 | ||
| GO-BP | Polysaccharide biosynthetic process | 0.005 | 10 | ||
| GO-MF | Transferase activity, transferring nitrogenous groups | 0.005 | 8 | ||
| GO-BP | Lipopolysaccharide metabolic process | 0.007 | 4 | ||
| IL-6 | GOM (1,3) | GO-BP | Regulation of cell morphogenesis involved in differentiation | 0.001 | 18 |
| GO-BP | Response to hypoxia | 0.005 | 25 | ||
| GO-BP | Gliogenesis | 0.011 | 16 | ||
| GO-BP | Immune response-activating cell surface receptor signaling | 0.013 | 13 | ||
| GO-MF | Steroid hormone receptor binding | 0.013 | 13 | ||
| GO-BP | Regulation of cell morphogenesis | 0.023 | 22 | ||
| GO-BP | Positive regulation of leukocyte chemotaxis | 0.023 | 9 | ||
| GO-BP | Immune response-regulating cell surface receptor signaling | 0.023 | 13 | ||
| GO-BP | Regulation of cAMP metabolic process | 0.031 | 19 | ||
| GO-BP | Regulation of leukocyte chemotaxis | 0.033 | 9 | ||
| TNF- | MAD (1) | GO-BP | Leukocyte differentiation | 0.003 | 16 |
| GO-BP | B cell activation | 0.004 | 13 | ||
| GO-BP | Cellular component morphogenesis | 0.005 | 28 | ||
| GO-BP | Lymphocyte differentiation | 0.008 | 15 | ||
| GO-BP | B cell differentiation | 0.012 | 11 | ||
| GO-MF | Small GTPase regulator activity | 0.014 | 22 | ||
| GO-BP | Hemopoietic or lymphoid organ development | 0.020 | 21 | ||
| KEGG | Primary immunodeficiency pathway | 0.020 | 10 | ||
| GO-BP | Regulation of T cell activation | 0.034 | 14 | ||
| GO-BP | Immune system development | 0.036 | 21 | ||
| PAI-1 | MAD (1,3) | GO-BP | Leukocyte differentiation | 0.004 | 18 |
| GO-MF | Magnesium ion binding | 0.005 | 38 | ||
| GO-BP | Lymphocyte differentiation | 0.006 | 17 | ||
| KEGG | Primary immunodeficiency pathway | 0.007 | 11 | ||
| GO-BP | Hemopoiesis | 0.009 | 25 | ||
| GO-BP | B cell activation | 0.009 | 14 | ||
| GO-BP | Hemopoietic or lymphoid organ development | 0.013 | 25 | ||
| GO-BP | T cell differentiation | 0.015 | 13 | ||
| GO-BP | T cell differentiation in the thymus | 0.020 | 10 | ||
| GO-BP | Immune system development | 0.029 | 25 |
In all tests, the unified set of co-methylated genes for different adipose depots that correlated to a phenotypic trait of obesity were compared with all known genes, which served as the background. P values (i.e. corrected EASE score), which indicated the significance of the overlap between various gene sets, was calculated using Benjamini-corrected modified Fisher's exact test. BP, biological process; MF, molecular function.